Alexander M. Lesokhin, MD, on Initial Safety Data for Elranatamab in Multiple Myeloma

Posted: Friday, July 8, 2022

Alexander M. Lesokhin, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, discusses phase II findings from the MagnetisMM-3 trial, which tested once-weekly elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma who had received no prior BCMA-targeted treatment. This agent, with a two step–up priming regimen, appeared to be well tolerated.